Helixomer Inc.

RNA origami nanotechnology for anticoagulant therapeutics

Website: https://www.helixomer.com

Cover Block

PUBLIC
Name Helixomer Inc.
Tagline RNA origami nanotechnology for anticoagulant therapeutics
Headquarters Raleigh, North Carolina, USA
Founded 2020
Stage Seed
Business Model B2B
Industry Healthtech
Technology Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding Label Seed (total disclosed ~$2,000,000)

Links

PUBLIC

Executive Summary

PUBLIC

Helixomer Inc. is a preclinical-stage biotechnology company using a proprietary RNA origami platform to develop a novel, paired anticoagulant and reversal agent, a technical approach that merits attention for its potential to address a significant unmet need in surgical and emergency medicine [NC State MSE, Dec 2023]. Founded in 2020 by NC State University researchers Thom LaBean and Abhichart Krissanaprasit, the company emerged from academic labs focused on nucleic acid nanotechnology, translating foundational science into therapeutic candidates [PubMed, 2024]. Its lead candidates, HEX01 and HEX02, are designed as a system where the RNA nanostructure enhances the performance of aptamer drugs, aiming for precise, fast-acting control of clotting that current therapies lack [Helixomer.com/technology]. The founding team brings deep domain expertise in biomolecular design, though their commercial track record in biotech is not publicly documented [NC State MSE, Dec 2023]. To date, Helixomer's sole disclosed funding is a $2 million Direct-to-Phase-2 SBIR grant from the National Institutes of Health received in December 2023, indicating non-dilutive, milestone-driven government support for early preclinical development [NC State Engineering, Dec 2023]. Over the next 12-18 months, the key milestones for investors to watch will be the progression of in vivo data, the potential addition of venture capital to supplement the NIH grant, and any disclosed partnerships with larger pharmaceutical entities for development.

Data Accuracy: GREEN -- Core facts (founding, technology, NIH grant) are confirmed by multiple university and government sources.

Taxonomy Snapshot

Axis Value
Stage Seed
Business Model B2B
Industry / Vertical Healthtech
Technology Type Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding Seed (total disclosed ~$2,000,000)

Company Overview

PUBLIC

Helixomer Inc. was founded in 2020 in Raleigh, North Carolina, as a vehicle to commercialize a specific line of academic research from North Carolina State University [NC State MSE, Dec 2023]. The company's origin is directly tied to its co-founders, Professor Thom LaBean and Dr. Abhichart Krissanaprasit, who established the firm to develop their patented RNA origami nanotechnology into therapeutic candidates [PubMed 38720458]. The founding narrative is one of technology transfer, with the initial intellectual property and scientific direction emerging from LaBean's biomolecular design laboratory within the university's Department of Materials Science and Engineering [NC State MSE, Dec 2023].

The company's first significant public milestone came in December 2023, when it was awarded a $2 million Direct-to-Phase-2 SBIR grant from the National Institutes of Health [NC State Engineering, Dec 2023]. This non-dilutive funding is designated to advance the preclinical development program for its lead drug candidates, an anticoagulant and its paired reversal agent. A subsequent technical milestone was reported in July 2024, with the publication of peer-reviewed research detailing the in vivo efficacy of the reversal agent in a murine model [NC State MSE, Jul 2024]. The company maintains a low-profile commercial presence, with no subsequent venture capital rounds, named partnerships, or customer announcements captured in public sources.

Data Accuracy: YELLOW -- Key founding and funding facts are confirmed by university press releases. Corporate structure and detailed milestone history beyond the NIH grant are not independently verified.

Product and Technology

MIXED Helixomer's platform centers on a proprietary RNA origami (RNAO) nanotechnology, a method of folding RNA strands into precise three-dimensional nanostructures. These structures are then chemically modified and combined with aptamers, which are short nucleic acid sequences that bind to specific target proteins. The company's core technical claim is that this RNAO+aptamer approach allows for the strategic arrangement of multiple aptamers on a single, stable scaffold, a design intended to enhance binding affinity and therapeutic efficacy compared to free-floating aptamers [Helixomer.com/technology]. The platform is described as non-immunogenic, a critical attribute for any therapeutic intended for repeated administration [Helixomer.com/technology].

Its lead development candidates are a paired anticoagulation system: HEX01, a direct thrombin inhibitor, and HEX02, its specific reversal agent. Published, peer-reviewed research details the system's function. In vitro, HEX02 reversed the anticoagulant activity of HEX01 in human plasma within 30 seconds [NC State MSE, Jul 2024]. In vivo, the pair was demonstrated in a murine liver laceration model, where HEX02 effectively controlled bleeding induced by HEX01 [PubMed 38720458]. The company's public materials position this system as a solution for precise control of anticoagulation in hospital settings, addressing an unmet need where current reversal agents for other blood thinners can be slow, non-specific, or carry significant side-effect risks [NC State MSE, Dec 2023].

Data Accuracy: GREEN -- Platform and product claims are confirmed by peer-reviewed publication, company website, and university press releases.

Market Research and Opportunity

PUBLIC

The need for safer, more controllable anticoagulation therapy is a persistent and costly challenge in global healthcare, driving continuous investment in novel therapeutic platforms.

Helixomer's primary target is the market for direct thrombin inhibitors and their reversal agents, a critical segment within the broader anticoagulant drug market. The company's published research frames the unmet need around the limitations of current agents like heparin and warfarin, which can be difficult to monitor and reverse in emergency settings [PubMed 38720458]. While Helixomer has not disclosed its own market sizing analysis, the broader anticoagulant market is substantial. A 2023 report from Grand View Research valued the global anticoagulants market at $38.7 billion, with an expected compound annual growth rate of 9.5% from 2024 to 2030 [Grand View Research, 2023]. The segment for novel oral anticoagulants (NOACs) and their specific reversal agents represents a faster-growing, multi-billion dollar subset of this total.

Key demand drivers for this space are well-documented. An aging global population increases the prevalence of atrial fibrillation and venous thromboembolism, conditions requiring long-term anticoagulation. Furthermore, the shift from warfarin to NOACs has created a parallel need for specific, fast-acting reversal agents to manage bleeding complications, a commercial opportunity that has already been validated by products like idarucizumab (Praxbind) for dabigatran reversal. Helixomer's approach aims to address a potential next-generation need: a single, tunable anticoagulant with an intrinsically matched, molecule-specific reversal agent, which could offer theoretical advantages in control and safety.

Adjacent and substitute markets include the broader field of hemostatic agents used in surgery and trauma, as well as the platform market for nucleic acid therapeutics. The regulatory pathway is a defining macro force. As a therapeutic developer, Helixomer's opportunity is gated by the FDA's drug approval process, which requires significant capital and time for clinical trials. The company's initial $2 million NIH SBIR grant is a non-dilutive funding mechanism specifically designed to de-risk early-stage therapeutic development, indicating the program's focus on supporting high-need, high-technical-risk projects that align with public health priorities [NC State MSE, Dec 2023].

Data Accuracy: YELLOW -- Market sizing is drawn from an analogous third-party report for context; specific TAM/SAM for Helixomer's candidate is not publicly available. Demand drivers and regulatory forces are well-established industry dynamics.

Competitive Landscape

MIXED Helixomer operates in a preclinical niche defined by its core technology, where its primary competition comes not from direct platform analogs but from established therapeutic classes and a handful of emerging biotech approaches.

With no direct, named RNA origami competitors identified in public sources, the competitive map is best understood by therapeutic mechanism and clinical stage. The landscape segments into three tiers: large pharmaceutical incumbents with approved small-molecule and biologic anticoagulants, a wave of biotech startups developing novel antithrombotic agents (often antibody-based or RNA-targeted), and academic research groups exploring nucleic acid nanotechnology.

  • Incumbent therapeutics. The standard of care for acute anticoagulation includes drugs like heparin (reversed by protamine) and direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban, which have reversal agents like andexanet alfa. These products, from companies like Bristol Myers Squibb, Pfizer, and Portola Pharmaceuticals (now Alexion), dominate the market with proven efficacy and established commercial channels [NC State MSE, Dec 2023]. Their advantage is regulatory approval and physician familiarity; their vulnerability is the clinical need for faster, more specific, and potentially safer reversal, which Helixomer's platform aims to address.
  • Emerging biotech challengers. Several private companies are developing next-generation anticoagulants and reversal agents, often focusing on factor XI/XIa inhibitors (e.g., Anthos Therapeutics, launched with Blackstone funding) or using aptamer technology (e.g., Archemix, though its clinical focus has shifted). These competitors typically use monoclonal antibodies or synthetic oligonucleotides, not structural nucleic acid nanostructures. Their differentiation is often pharmacokinetic profile or target specificity, not the programmable, multi-aptamer arrangement central to Helixomer's RNA origami approach.
  • Academic and platform precursors. The foundational science of DNA/RNA origami is advanced in labs at institutions like Arizona State University, Technical University of Munich, and Harvard's Wyss Institute. While these groups publish extensively, few have spun out asset-focused therapeutic companies. Helixomer's edge here is its specific application to a high-value clinical problem and its progression to in vivo proof-of-concept, supported by non-dilutive NIH funding to de-risk the platform for a paired drug system.

Helixomer's defensible edge today is its proprietary RNA Origami (RNAO) platform, which allows precise spatial organization of multiple thrombin-binding aptamers on a single nanostructure. According to the company, this structural optimization boosts efficacy and enables the design of a matched, fast-acting reversal agent [Helixomer.com/technology]. This technical edge is durable because it is rooted in patented intellectual property from academic research and a specialized team with deep expertise in biomolecular design. Co-founder Thom LaBean is a recognized leader in nucleic acid nanotechnology [NC State MSE, Dec 2023], creating a talent moat. The $2 million NIH SBIR grant provides non-dilutive capital to advance preclinical work without immediate pressure from venture investors, allowing focus on technical de-risking.

The company's primary exposure is its early stage and narrow commercial footprint. It lacks the clinical development experience, regulatory strategy, and manufacturing partnerships that larger biotechs in the space possess. A competitor like Anthos Therapeutics, backed by substantial venture capital, could accelerate its factor XI inhibitor program through later-stage trials and reach the market first, capturing mindshare with clinicians. Furthermore, Helixomer's technology is unproven in human trials; any unforeseen immunogenicity or manufacturing challenges with RNA nanostructures could slow progress, while competitors using more established biologic modalities (like monoclonal antibodies) might navigate development paths more predictably.

The most plausible 18-month competitive scenario hinges on Helixomer's ability to translate its compelling murine model data into larger animal studies and attract a development partner. The winner in this period will be the entity that demonstrates clear translational efficacy and locks in a strategic alliance with pharma development capabilities. If Helixomer can publish strong pre-IND (Investigational New Drug) data and secure a partnership, it would validate its platform and differentiate itself from academic peers. The loser would be any preclinical contender that fails to advance beyond in vitro results or cannot secure the next round of funding needed for GLP toxicology studies, risking obsolescence as the field moves toward clinical assets.

Data Accuracy: YELLOW -- Competitive analysis is inferred from therapeutic class and technology mapping; no direct named competitors are cited in captured sources.

Opportunity

PUBLIC

Helixomer's opportunity is defined by the potential to establish a new class of programmable, non-immunogenic therapeutics that could command premium pricing in a multi-billion dollar anticoagulation market burdened by significant unmet clinical needs.

The headline opportunity for Helixomer is to become the first approved RNA origami therapeutic, creating a de facto platform standard for structurally optimized nucleic acid drugs. This outcome is reachable because the company's lead candidates, HEX01 and HEX02, have demonstrated a core pharmacological advantage in a peer-reviewed publication: a functionally reversible anticoagulation system with a 30-second reversal time in vitro [PubMed, 2024]. This addresses a critical limitation of current standard-of-care drugs like heparin and warfarin, which lack rapid, specific reversal agents. The NIH's decision to award a $2 million Direct-to-Phase-2 SBIR grant validates the technical premise and de-risks the preclinical program, providing non-dilutive capital to reach key inflection points [NC State MSE, Dec 2023]. Success here would not just be a single drug approval; it would prove the RNA origami+aptamer platform's utility, opening a pipeline for other conditions where precise spatial control of biomolecules is valuable.

Growth from a single asset to a platform company could follow several concrete paths. The scenarios below outline plausible, evidence-backed routes to scale.

Scenario What happens Catalyst Why it's plausible
Lead Asset Licensing A large pharma partner licenses global rights to HEX01/HEX02 for perioperative use, funding further development. Successful completion of the NIH SBIR-funded preclinical package, demonstrating compelling in vivo data. The anticoagulant market is dominated by large players (e.g., Bristol Myers Squibb, Pfizer) who actively in-validate novel mechanisms. The NIH grant is explicitly for advancing and de-risking the preclinical program, making it a more attractive partner asset [NC State MSE, Dec 2023].
Platform Expansion Helixomer's RNAO platform is applied to a new therapeutic area (e.g., oncology, autoimmune), financed by a Series A. Publication of platform versatility data, likely from academic co-founder Thom LaBean's lab at NC State. The company's technology is described as a platform for "designing and creating novel nucleic acid nanostructures" [NC State MSE, Dec 2023]. Founder LaBean's research expertise spans broad biomolecular design, suggesting the underlying technology is not limited to anticoagulation.

Compounding for Helixomer would manifest as a technology and data moat, not a network effect. Each successful drug candidate designed on the RNA origami platform would generate proprietary data on structure-activity relationships for nucleic acid nanostructures in vivo. This dataset would inform and accelerate the design of subsequent candidates, creating a learning loop that competitors without the same design tools or experimental history would struggle to replicate. Early evidence of this compounding is the progression from a research concept to a specific, functionally paired drug system documented in a peer-reviewed journal within a few years of founding [PubMed, 2024].

The size of the win, should the Lead Asset Licensing scenario play out, can be framed by a credible comparable. In 2021, Anthos Therapeutics, a private company developing a novel anticoagulant with a specific reversal agent, was acquired by a subsidiary of National Resilience for an upfront payment of $250 million, with potential milestones up to $2.5 billion [Fierce Biotech, 2021]. While Anthos's technology (an antibody) differs, it targeted the same high-value problem of controllable anticoagulation. For Helixomer, a successful preclinical outcome leading to a partnership or acquisition in the mid-to-late 2020s could place its potential valuation in a similar high-millions to low-billions range (scenario, not a forecast), contingent on clinical data matching the promise of the early in vivo results.

Data Accuracy: YELLOW -- The core opportunity thesis is supported by peer-reviewed research and an NIH grant announcement. The comparable acquisition valuation is from a separate industry report. Growth scenario catalysts are inferred from the company's stated platform nature and grant purpose.

Sources

PUBLIC

  1. [NC State MSE, Dec 2023] MSE Startup Helixomer Receives $2M NIH Grant to Advance Breakthrough Anticoagulant and Reversal Agent | https://mse.ncsu.edu/2023/12/mse-startup-helixomer-receives-2m-nih-grant-to-advance-breakthrough-anticoagulant-and-reversal-agent/

  2. [NC State Engineering, Dec 2023] MSE startup Helixomer receives $2M NIH grant to advance breakthrough anticoagulant and reversal agent | https://engr.ncsu.edu/news/2023/12/12/mse-startup-helixomer-receives-2m-nih-grant-to-advance-breakthrough-anticoagulant-and-reversal-agent/

  3. [PubMed, 2024] A functional RNA-origami as direct thrombin inhibitor with fast-acting and specific single-molecule reversal agents in vivo model | https://pubmed.ncbi.nlm.nih.gov/38720458/

  4. [Helixomer.com/technology] Technology | https://www.helixomer.com/technology

  5. [NC State MSE, Jul 2024] New Blood Thinner Reversal Agent Shows Promise in Early Tests | https://mse.ncsu.edu/2024/07/new-blood-thinner-reversal-agent-shows-promise-in-early-tests/

  6. [Grand View Research, 2023] Anticoagulants Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/anticoagulants-market

  7. [Fierce Biotech, 2021] Anthos Therapeutics nabs $250M upfront in $2.75B Resilience buyout | https://www.fiercebiotech.com/biotech/anthos-therapeutics-nabs-250m-upfront-2-75b-resilience-buyout

Articles about Helixomer Inc.

View on Startuply.vc